Unknown primary tumour of the head and neck
Conditions
Brief summary
Macroscopic fluorescent signal levels and tracer distribution observed with TFE, Detection rates of TFE and WLE
Detailed description
Patient characteristics (age, sex, BMI, history and morbidity, localization of primary tumor and lymph node metastasis, vital parameters and presence of symptoms before and after tracer administration), Macroscopic fluorescent signal levels and tracer distribution observed with flexible fluorescence laryngoscopy, Quantification of intrinsic fluorescence signals observed using the MDSFR/SFF probe, Macroscopic fluorescent signal levels and tracer distribution observed with ex vivo imaging of FSA and mucosectomy specimens, Histopathologic characteristics of biopsied specimens including HPV-status, Results of the quality of life questionnaires QLQ-C30, QLQH&N35 and SWAL-QOL
Interventions
DRUGErbitux 5 mg/mL solution for infusion
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Macroscopic fluorescent signal levels and tracer distribution observed with TFE, Detection rates of TFE and WLE | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient characteristics (age, sex, BMI, history and morbidity, localization of primary tumor and lymph node metastasis, vital parameters and presence of symptoms before and after tracer administration), Macroscopic fluorescent signal levels and tracer distribution observed with flexible fluorescence laryngoscopy, Quantification of intrinsic fluorescence signals observed using the MDSFR/SFF probe, Macroscopic fluorescent signal levels and tracer distribution observed with ex vivo imaging of FSA and mucosectomy specimens, Histopathologic characteristics of biopsied specimens including HPV-status, Results of the quality of life questionnaires QLQ-C30, QLQH&N35 and SWAL-QOL | — |
Countries
Netherlands
Outcome results
None listed